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Abstract
To evaluate the ability of a radiomics signature based on 3T dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) to
distinguish between low and non-low Oncotype DX (OD) risk groups in estrogen receptor (ER)-positive invasive breast cancers.
Between May 2011 and March 2016, 67 women with ER-positive invasive breast cancer who performed preoperative 3T MRI and
OD assay were included. We divided the patients into low (OD recurrence score [RS]<18) and non-low risk (RS≥18) groups.
Extracted radiomics features included 8 morphological, 76 histogram-based, and 72 higher-order texture features. A radiomics
signature (Rad-score) was generated using the least absolute shrinkage and selection operator (LASSO). Univariate and multivariate
logistic regression analyses were performed to investigate the association between clinicopathologic factors, MRI ﬁndings, and the
Rad-score with OD risk groups, and the areas under the receiver operating characteristic curves (AUC) were used to assess
classiﬁcation performance of the Rad-score.
The Rad-score was constructed for each tumor by extracting 10 (6.3%) from 158 radiomics features. A higher Rad-score (odds
ratio [OR], 65.209; P<.001), Ki-67 expression (OR, 17.462; P= .007), and high p53 (OR=8.449; P= .077) were associated with
non-low OD risk. The Rad-score classiﬁed low and non-low OD risk with an AUC of 0.759.
The Rad-score showed the potential for discrimination between low and non-low OD risk groups in patients with ER-positive
invasive breast cancers.
Abbreviations: AUC = area under the curve, BI-RADS = Breast Imaging Reporting and Data System, CAD = computer-aided
diagnosis, DCE = dynamic contrast-enhanced, EIC = extensive intraductal component, ER = estrogen receptor, LASSO = logistic
least absolute shrinkage and selection operator, LVI= lymphovascular invasion, MRI=magnetic resonance imaging, OD=Oncotype
DX, PR = progesterone receptor, ROC = receiver operating characteristic, ROI = region of interest, RS = recurrence Score.
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The Oncotype DX (OD) genomic assay (Oncotype DX, Genomic
Health, CA) evaluates the expression of a panel of 21 genes from
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Nam et al. Medicine (2019) 98:23 Medicinerecurrence score (RS). According to Paik et al,[2] the rate of
distant recurrence at 10 years in patients with a low RS (6.8%)
was signiﬁcantly lower than in those with a high RS (30.5%),
while another study showed that RS predicts the magnitude of
chemotherapy beneﬁt.[3] Thus, in their treatment guidelines for
early breast cancer, the American Society of Clinical Oncology
strongly recommends chemotherapy in patients with a high RS
(>30), not low RS (<18).[10] However, the OD assay is
performed on tissue samples, involves additional tumor handling,
and is expensive.[11,12] Therefore, a non-invasive means of
distinction in patients whomay be treated without chemotherapy
would facilitate treatment decision-making, cost-reduction, and
chemotherapy-induced toxicity avoidance.
Radiomics is a ﬁeld that converts imaging data into high-
dimensional, mineable, and quantitative features, including
characteristics that are imperceptible to the human eye.[13–15]
Radiomics research with genomic information, or “radiogenom-
ics”, is a relatively new ﬁeld of research.[16] The aim of
radiogenomics is to correlate imaging characteristics (i.e., the
imaging phenotype) with underlying gene expression patterns,
gene mutations, and other genome-related characteristics.[16]
Radiogenomics literature on brain, breast, and lung cancers,
amongothers, is growing.[16–20] In radiogenomic research inbreast
imaging, correlation withODmight be representative topic. There
are several studies that have identiﬁed radiomics features on
magnetic resonance imaging (MRI) that might be associated with
OD RS. Sutton et al[15] reported that morphological and texture-
based MRI features correlated with OD RS, while another study
showed that 31 extracted multi-parametric MRI (1.5T) features
correlated with OD RS.[21] However, both studies used a limited
number of features to derive a predictive biomarker. While the
features, as individual predictors, were signiﬁcantly associated
with prognosis prediction in patients with breast cancer, the
combined analysis of a panel ofmultiple predictors as a signature is
more powerful for assisting clinical management.[22,23] Radiomics
enablesmultiple imaging features to be investigated in parallel and
thus facilitates the construction of powerful signatures.[13,14]
Recently, radiomics signatures were found to be predictive in non-
small cell lung cancer and colorectal cancer.[24–26] To our
knowledge, the correlation between radiomics signature and
OD risk classiﬁcation is currently unclear.
Therefore, the purpose of this study was to evaluate the ability
of a radiomics signature based on 3T dynamic contrast-enhanced
(DCE)-MRI to distinguish between low and non-low OD risk
groups in patients with ER-positive invasive breast cancers.
2. Materials and methods
2.1. Study population
Our Institutional Review Board approved this retrospective study
and informed consent was waived.
We identiﬁed 127 women with ER-positive invasive breast
cancer who underwent preoperative breast MRI and a validated
gene expression assay (Oncotype DX; Genomic Health,
Redwood City, Calif) at our institution, from May 2011 to
March 2016. The study inclusion criteria were:(1) completion of preoperative 3T DCE-MRI at our institution,
(2) initial unilateral breast malignancy, and
(3) a lesion manifesting as a mass at MRI. Patients who already
had a malignancy in another organ (metastasis or primary
malignancy) were excluded. Finally, the study population2included 67 women (mean age, 45.1 years; range, 28–66
years).
2.2. Magnetic resonance imaging protocol
MRI was performed using a 3T Achieva scanner (Philips Medical
Systems, Best, The Netherlands), with a dedicated bilateral phase
array breast coil, in the prone position. The MRI examination
consisted of turbo spin-echo T1- and T2- weighted sequences,
and a 3-dimensional DCE sequence. Details of sequence
parameters are described in Appendix S1, http://links.lww.
com/MD/D22. For dynamic contrast enhancement, a 0.1 mmol/
kg bolus of Gadobutrol (Gadovist; Bayer Healthcare Pharma-
ceutical, Berlin, Germany) was injected, followed by a 20-mL
saline ﬂush.2.3. Magnetic resonance imaging preparation for
radiomics analysis
T2-weighted, pre-enhanced T1-weighted, contrast-enhanced T1-
weighted and contrast-enhanced T1-weighted subtraction MR
images were retrieved from the Picture Archiving Communica-
tion System and loaded onto a workstation for further radiomics
analysis. Subtraction images, from contrast-enhanced images at
90 s to pre-enhanced images and contrast-enhanced T1-weighted
images at 90 s after contrast injection, were assessed. The images
were reviewed by a radiologist with 12 years of experience in
breast MRI (ESK.). In every slice, the radiologist drew a region of
interest (ROI) around the visible tumor on the contrast-enhanced
T1-weighted subtraction images. Finally, the ROIs covered the
entire 3D volume of the tumor for volumetric segmentation. The
deﬁned ROI was co-registered onto the other 3 image series using
a 9-parameter afﬁne transform with mutual information as the
similarity measure.[27] The ROI was drawn as large as possible
but did not include edge voxels to avoid a partial volume effect. In
multifocal or multicentric disease, the largest tumor was selected
as an index cancer for analysis.
2.4. Conventional magnetic resonance imaging and
clinicopathological evaluation
The MR images of included masses were retrospectively
evaluated, according to the American College of Radiology
Breast Imaging Reporting and Data System (ACR BI-RADS) MR
lexicon,[28] by 2 board-certiﬁed radiologists (JSC and ESK, with 8
and 12 years of experience in breast MR imaging, respectively) in
consensus. The radiologists assessed the shape (oval/round,
or irregular), margin (circumscribed, irregular, or spiculated),
and internal enhancement characteristics (homogeneous, hetero-
geneous, or rim) of each mass.
All T1-weighted images were transferred to a computer-aided
diagnosis (CAD) system (CAD stream, version 4.1.3, Merge
Healthcare, Chicago, IL), a commercially available CAD system.
Pixel values at the pre-contrast and second contrast-enhanced
series (90s after contrast injection) were compared to classify
enhancement. If the pixel value increased above a threshold of
50%, it was shown in color. Color was assigned according to
changes in pixel values, between the second contrast-enhanced
and delayed contrast-enhanced series, as follows: persistent type
indicated an increased pixel signal intensity greater than 10%
from the second post-contrast series; washout type indicated
decreased pixel signal intensity at the last post-contrast series
Nam et al. Medicine (2019) 98:23 www.md-journal.comgreater than 10% from the second post-contrast series; plateau
type indicated change in neither direction by more than 10%.We
chose the most suspicious kinetic curve component within the
tumors. CAD report was prospectively saved by a research
assistant. The following parameters were used in our analysis:
peak enhancement value (%), most suspicious enhancement
kinetics of delayed phase (persistent, plateau, or washout), and
percentage of washout.
The ﬁnal histopathologic results of surgical specimens were
reviewed to determine tumor type, size, histologic grade, presence
of an extensive intraductal component (EIC), lymphovascular
invasion (LVI), ER, progesterone receptor (PR), Ki-67, and p53
status. ER and PR positivity were determined by using a cutoff
value of less than 1% positively stained nuclei. We reviewed the T
stage and N stage after surgery.2.5. Statistical analysis
Statistical analyses were performed using R software (version
3.2.4; R Foundation for Statistical Computing, Vienna, Austria),
and statistical signiﬁcance was accepted where P values
were<.05. The minimum required sample size was 14 which
was computed with 2 tailed signiﬁcance of 0.05 and power of
0.95 to detect RS score change of 10.[29]2.6. Patient characteristics according to Oncotype DX
recurrence score risk group
Patient characteristics, including clinicopathologic (age at
diagnosis, tumor type, tumor size, histologic grade, presence of
EIC, LVI, ER, PR, Ki-67, p53, T stage, and N stage), MRI
ﬁndings according to BI-RADS lexicon (tumor shape, margin,
and internal enhancement characteristics), and kinetic features
assessed by CAD (the most suspicious enhancement kinetics of
delayed phase, peak enhancement value [%], and percentage of
washout) among low (RS<18), intermediate (RS 18–30), and
high (RS>30) OD risk groups were compared using analysis of
variance (ANOVA) for continuous variables, and Chi-square and
Fisher exact tests for categorical variables.2.7. Radiomics analysis and score building
Radiomics features from 4 MRI series were automatically
computed over radiologist-drawn ROIs. The features were
computed using a combination of open source code[30] and in-
house generated computer code implemented in MATLAB
(Mathworks Inc. Natick, MA). For most features, we used the
open source software PyRadiomics so that the results could be
easily reproduced. For the features not available in PyRadiomics,
we used our in-house MATLAB code. The in-house code is
attached as the supplement. The features were grouped into
morphological (8 features), histogram-based (19 features), and
higher-order texture features (18 features). A total of 158 features
in 3 different categories were computed. In Appendix S2, http://
links.lww.com/MD/D22 and Appendix Table 1, http://links.lww.
com/MD/D22, categorical concepts of radiomics features
(Appendix S2, http://links.lww.com/MD/D22) and the mathe-
matical deﬁnition of adopted feature algorithms (Appendix
Table 1, http://links.lww.com/MD/D22) are described. The
features were z-score normalized. We adopted the least absolute
shrinkage and selection operator (LASSO) method, a popular
regularized machine learning method for high-dimensional data,3to identify signiﬁcant radiomics features related to the primary
outcome. The LASSO encourages the selected features to be
orthogonal. A leave-1-out cross validation (LOOCV) was
adopted to separate train and test data. Each iteration of
LOOCV led to possibly different models and we kept the features
and models that appeared more than 55% during the LASSO
procedure to identify the stable features and models. We applied
the user chosen threshold of 55% obtain a few stable features.
Lowering the threshold might lead to too many unstable features
and increasing the threshold might lead to having no common
features. Our choice was a middle ground between 2 extremes. A
radiomics signature (Rad-score) was calculated for each patient
via a linear combination of selected radiomics features weighted
by their respective coefﬁcients. The coefﬁcients were the mean
values of the stable models.2.8. Validated factors selection for predicting Oncotype
DX recurrence score
Univariate logistic regression analyses were conducted with
clinicopathologic, MRI ﬁndings according to BI-RADS lexicon,
kinetic features assessed on CAD, and Rad-score, to ﬁnd the
signiﬁcant factors for classifying low and non-low (intermediate
and high) OD risk groups. The variables with P values<.05 were
included in the multivariate logistic regression model. To avoid
multicollinearity, we further performed stepwise selection using
Akaike information criterion (AIC).
Receiver operating characteristic (ROC) curves using LOOCV
were used to compare the performances of the Rad-score only,
clinicopathologic, and combined models for predicting low and
non-low OD risk groups. We computed area under the curve
(AUC) values for numerical comparison.
The overall scheme of our pipeline is given in Figure 1.
3. Results
3.1. Patient characteristics according to the Oncotype DX
recurrence score risk groups
Of the 67 patients, 45 (67.2%) were classiﬁed as low-risk, 19
(28.4%) intermediate-risk, and 3 (4.5%) high-risk. We further
classiﬁed into 2 groups: low-risk (45/67, 67.2%), and non-low-
risk (22/67, 32.8%). The median OD RS was 14 (range 3–39).
Patients’ characteristics according to OD risk are summarized
in Table 1. All 67 patients were ER-positive and HER2-negative.
Among the clinical, pathologic, and radiologic parameters, a
higher histologic grade (P<.001), PR negativity (P<.001), high
Ki-67 expression (P<.001), p53 overexpression (P<.001), and
oval/round shape (P=.038) were associated with higher OD RS.
In 59 (88.1%) of the 67 MRI examinations, CAD reports were
available.3.2. Radiomics analysis and Rad-score building
One hundred ﬁfty-six radiomics features were reduced to
10 (6.2%) potential predictors. The radiomics features with
a nonzero coefﬁcient in the LASSO regression model were as
follows: 6 histogram-based features (Min_val_T2, Skew-
ness_PRE T1, Skewness_Sub T1, Skewness_T2, Energy_val_Sub
T1, and percentile_histogram.2.5_T2) and 4 higher-order texture
features (Contrast_glcm_val_T2, Max_probability_val_Sub T1,
Variance_glcm_val_CE T1, and Sum_variance_val_PRE T1).
Figure 1. The overall scheme of the pipeline for present study.
Table 1
Characteristics of 67 patients with estrogen receptor (ER)-positive invasive breast cancers according to Oncotype DX risk groups.
Oncotype DX recurrence score
Variable
Low
(n=45)
Intermediate
(n=19)
High
(n=3) P value
Recurrence score 12.00±3.26 22.74±3.87 35.67±2.89 <.001
Patient age, yr
∗
45.29±8.00 44.00±6.82 49.33±10.26 .526
Tumor type .721
IDC 41 (91.1) 19 (100.0) 3 (100.0)
ILC 3 (6.7) 0 (0.0) 0 (0.00)
Mucinous carcinoma 1 (2.2) 0 (0.0) 0 (0.00)
Tumor size, cm
∗
1.70±0.69 1.73±0.86 1.10±0.87 .386
Histologic grade <.001
1 24 (53.3) 4 (21.1) 0 (0.00)
2 20 (44.4) 14 (73.7) 0 (0.00)
3 1 (2.2) 1 (5.3) 3 (100.0)
Extensive intraductal component .234
Absent 29 (64.4) 15 (78.9) 1 (33.3)
Present 16 (35.6) 4 (21.1) 2 (66.7)
Lymphovascular invasion .438
Absent 29 (64.4) 12 (63.2) 3 (100.0)
Present 16 (35.6) 7 (36.8) 0 (0.0)
PR <.001
Negative 0 (0.0) 2 (10.5) 2 (66.7)
Positive 45 (100.0) 17 (89.5) 1 (33.3)
Ki-67 <.001
<14% 37 (82.2) 8 (42.1) 0 (0.0)
≥14% 8 (17.8) 11 (57.9) 3 (100.0)
p53 <.001
Negative 43 (95.6) 14 (73.7) 0 (0.0)
Positive 2 (4.4) 5 (26.3) 3 (100.0)
T stage .870
1 35 (77.8) 14 (73.7) 2 (66.7)
2 10 (22.2) 5 (26.3) 1 (33.3)
N stage .596
0 35 (77.8) 14 (73.7) 3 (100.0)
1 10 (22.2) 5 (26.3) 0 (0.0)
(continued )
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Table 1
(continued).
Oncotype DX recurrence score
Variable
Low
(n=45)
Intermediate
(n=19)
High
(n=3) P value
Tumor shape .038
Oval or round 19 (42.2) 13 (68.4) 0 (0.0)
Irregular 26 (57.8) 6 (31.6) 3 (100.0)
Tumor margin .334
Circumscribed 20 (44.4) 12 (63.2) 1 (33.3)
Not circumscribed 25 (55.6) 7 (36.8) 2 (66.7)
Internal enhancement .054
Homogeneous 32 (71.1) 12 (63.2) 2 (66.7)
Heterogeneous 10 (22.2) 1 (5.3) 1 (33.3)
Rim enhancement 3 (6.7) 6 (31.6) 0 (0.0)
Enhancement kinetics of delayed phase (n=59) .616
Persistent 1 (2.5) 0 (0.0) 0 (0.0)
Plateau 1 (2.5) 2 (11.8) 0 (0.0)
Washout 38 (95.0) 15 (88.2) 2 (100.0)
Peak enhancement value
∗
347.15±160.81 322.71±124.64 471.00±111.72 .416
Percentage of washout
∗
31.20±25.19 28.12±23.07 18.50±17.68 .729
IDC= invasive ductal carcinoma, ILC= invasive lobular carcinoma, PR=progesterone receptor, RS= recurrence score.
∗
Data are means ± standard deviation, Data in parentheses are percentages.
Table 2
Univariate logistic regression analyses of the variables associated
with predicting non-low Oncotype DX risk.
Variable Odds ratio Standard Error P value
Rad-score 17.775 0.760 <.001
Age, yr 0.990 0.034 .779
Tumor type
IDC Ref Ref
ILC 0.000 2284.102 .994
Mucinous carcinoma 0.000 3956.180 .997
Tumor size, cm 0.888 0.361 .742
Histologic grade
1 Ref Ref
2 4.200 0.643 .026
Nam et al. Medicine (2019) 98:23 www.md-journal.comThe radiomics signature was constructed with a Rad-score,
calculated using the following formula:
Rad-score =Min_val_T2 x 0.0259 + Skewness_T2 x 0.0903 +
percentile_histogram.2.5_T2 x 0.0798 + Contrast_glcm_val_T2
x (0.0048) + Skewness_Sub T1 x 0.0055 + Energy_val_Sub
T1 x (0.0708) + Max_probability_val_Sub T1 x 0.0495 +
Skewness_PRE T1 x (0.0608) + Sum_variance_val_PRE T1 x
0.0399 + Variance_glcm_val_CE T1 x (0.0190).
The median Rad-score yielded -0.0676 (range, 0.2439–
0.1758; interquartile range, 0.1564–0.0352) in 45 low-risk
patients and 0.1197 (range, 0.1681–0.4245; interquartile
range, 0.0013–0.2521) in 22 non-low risk patients. The median
Rad-score of 67 patients was 0.0258 (range, 0.2439–0.4245;
interquartile range, 0.1262–0.0985).3 23.999 1.242 .010
Extensive intraductal component
Absent Ref Ref
Present 0.680 0.571 .499
Lymphovascular invasion
Absent Ref Ref
Present 0.846 0.554 .762
PR
Negative Ref Ref
Positive 0.000 1978.090 .993
Ki-67
<14% Ref Ref
≥14% 8.093 0.590 <.001
p53
Negative Ref Ref
Positive 12.280 0.848 .003
T stage
1 Ref Ref
2 1.313 0.598 .649
N stage
0 Ref Ref
1 1.029 0.622 .963
Tumor shape
(continued )3.3. Prediction models for Oncotype DX recurrence score:
buildings and performances
In univariate analysis, a higher Rad-score (odds ratio [OR],
17.775; P<.001), higher histologic grade (grade 2 [OR, 4.200;
P= .026]; grade 3 [OR, 23.999; P= .010]), high Ki-67 expression
(OR, 8.093; P<.001), and p53 overexpression (OR, 12.280;
P= .003) were associated with non-low OD risk (Table 2). We
considered 2 multivariate logistic regression models. For a
clinicopathologic model, a multivariate logistic regression with
stepwise selection was performed for clinicopathologic factors,
and Ki-67 (OR, 4.878; P= .015) and p53 (OR, 4.972; P= .086)
were selected as predictors. For the combined model, we included
Rad-score in the multivariate logistic regression model and then
performed stepwise selection. The Rad-score and Ki-67, and p53
overexpression were selected from the procedure and a higher
Rad-score (OR, 65.2092; P<.001), high Ki-67 expression (OR,
17.462; P= .007), and high p53 (OR=8.449; P= .077) were
associated with non-low OD risk (Table 3).
ROC curve analysis using a logistic regression model, with
Rad-score-only model, yielded an AUC of 0.759. The clinico-
pathologic model, with Ki-67 and p53 as the predictors, yielded5
Table 3
Multivariate logistic regression analyseswith stepwise selection of
variables associated with predicting non-low Oncotype DX risk.
Model/Variable Odds ratio Standard Error P value
Clinicopathologic model
Ki-67 4.878 0.653 .015
p53 4.972 0.934 .086
Combined model
Rad-score 65.209 1.137 <.001
Ki-67 17.462 1.072 .007
p53 8.449 1.207 .077
Table 3
(continued).
Variable Odds ratio Standard Error P value
Oval or round Ref Ref
Irregular 0.506 0.528 .197
Tumor margin
Circumscribed Ref Ref
Not circumscribed 0.554 0.527 .262
Internal enhancement
Homogeneous Ref Ref
Heterogeneous 0.457 0.838 .350
Rim 4.572 0.776 .050
Enhancement kinetics of delayed phase
Persistent Ref Ref
Plateau 11513145.184 1455.398 .991
Washout 2576648.290 1455.398 .992
Peak enhancement value, % 1.000 0.002 .832
Percentage of washout, % 0.993 0.012 .541
HER2=human epidermal growth factor 2, IDC= invasive ductal carcinoma, ILC= invasive lobular
carcinoma, PR=progesterone receptor.
Figure 2. Receiver operating characteristic curves and area under the receiver
operating characteristic values from 3 different models: a) Rad-score-only
model, b) clinicopathologic model, and c) combined model.
Nam et al. Medicine (2019) 98:23 Medicinean AUC of 0.574. For the combined model, the AUC increased to
0.900 (Fig. 2). The optimal cut-off for the Rad-score model was
0.154. Figures 3 and 4 show the representative cases in the low
and non-low risk groups along with corresponding radiomics
feature values.4. Discussion
In this study, we investigated a quantitative radiomics signature
for ER-positive invasive breast cancers on 3T DCE-MRI and
assessed whether there was an association with OD RS.
Multivariate analyses revealed that a higher Rad-score (OR,
65.209; P<.001), high Ki-67 expression (OR, 17.462; P= .007),
and high p53 (OR=8.449; P= .077) are associated with non-low
OD risk. ROC curve analyses showed that the risk classiﬁcation
performance of the Rad-score-only model (AUC=0.759) was
better than the clinicopathological model (AUC=0.574), and the
best performance was achieved when the Rad-score was added to
clinicopathological model (AUC=0.900).
The OD currently represents the most commonly used
multigene assay that has been validated for both the prediction
of chemotherapy treatment beneﬁt and the estimation of the risk
of distant recurrence in patients with ER-positive, early-stage
breast cancer.[1,31] Paik et al[3] in the National Surgical Adjuvant6Breast and Bowel Project (NSABP) B-20 trial reported that
patients with high RS tumors (>30) had a large beneﬁt from
chemotherapy and patients with low RS (<18) derived minimal
beneﬁt from chemotherapy. Similar ﬁndings have been reported
for node-positive patients. In the Southwest Oncology Group
(SWOG) 8814 trial, Albain et al[8] showed that RS was strong
predictive factor of chemotherapy beneﬁt for 10-year disease-free
survival, but there was no apparent beneﬁt for scores <18 or 18
to 30. In addition to the prediction of chemotherapy beneﬁt, Paik
et al[2] in the NSABP B-14 trial reported that rate of 10-year
distant recurrence in the low-risk group (RS<18) was signiﬁ-
cantly lower in comparison with the high-risk group (RS>30) in
the patients with node-negative, tamoxifen-treated breast cancer.
The Arimidex, Tamoxifen, Alone or in Combination (ATAC)
study by Dowsett et al[9] demonstrated that RS was signiﬁcantly
associated with time to distant recurrence for both node-negative
and node-positive patients.
As an effort to predict OD RS by using MRI, several studies
have identiﬁed radiomics MRI features associated with OD
assay. Ashraf et al[21] utilized 4 intrinsic imaging phenotypes
extracted with 31 morphologic, kinetic, and spatial heterogeneity
1.5TDCE-MRI features, and explored their correlationwithOD;
phenotypes 1 and 2 consisted entirely of tumors with an RS<31
and included only low- and intermediate- risk tumors. Sutton
et al[15] reported similar results while investigating 44 morpho-
logic and texture imaging DCE-MRI features at 1.5T or 3.0T;
multivariate analyses identiﬁed 2 texture features (kurtosis on the
ﬁrst [P= .0056] and third [P= .0005] post-contrast sequences)
that signiﬁcantly correlated with recurrence scores. A correlation
study by Wan et al[32] showed that various computer-extracted
texture DCE-MRI features at 1.5T were highly correlated with
high and low OD risk classiﬁcations for ER-positive breast
cancers, although they only included patients with low (<18) and
high (>30) OD RS, excluding intermediate RS (18–30).
Figure 3. The representative MRI images in the non-low risk group along with corresponding radiomics feature values in a 58-year-old woman with invasive ductal
carcinoma. Her OD RS was 34 and categorized as non-low risk group. Rad-score based on radiomic features was 0.42, which was concordant with the category
assessed by OD RS. MRI=magnetic resonance imaging, OD=Oncotype DX, RS= recurrence score.
Figure 4. The representative MRI images in the low risk group along with corresponding radiomics feature values in a 33-year-old woman with invasive ductal
carcinoma. Her OD RS was 12 and categorized as low risk group. Rad-score based on radiomic features was -0.20, which was concordant with the category
assessed by OD RS. MRI=magnetic resonance imaging, OD=Oncotype DX, RS= recurrence score.
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features on small patient cohorts using different machines.
For Rad-score construction, 156 candidate radiomics features
were reduced to 10 potential predictors by using the LASSO
method. The combined analyses of a panel of multiple predictors
as a radiomics signature has been embraced in recent studies[24–
26] to estimate disease-free survival in early-stage non-small cell
lung cancer[24] and predict lymph node metastasis in colorectal
cancer.[26] Although the AUC (0.900) of the combinedmodel was
still incomplete to replace OD RS, the Rad-score showed the7potential for a noninvasive, fast, economic, and repeatable
method for use during treatment in routine practice, which could
replace more expensive genomic testing. To the best of our
knowledge, this is the ﬁrst attempt to investigate the association
between OD RS classiﬁcations and a radiomics signature, as well
as various clinicopathologic and conventional MRI ﬁndings,
including CAD data.
Among the established histopathologic parameters, high Ki-67
expression (OR, 17.462; P= .007) remained a signiﬁcant factor
associated with the non-low OD risk group. Our results are
Nam et al. Medicine (2019) 98:23 Medicineconsistent with other research. Williams et al[12] showed that
Ki-67 was signiﬁcantly associated with OD RS, Nottingham
grade, and angiolymphatic invasion. Sahebjam et al[33] reported a
strong correlation between Ki-67 and OD RS, especially in
tumors with a Ki-67 value ≥25%. Moreover, the likelihood of a
tumor with a Ki-67 value≥25%with an intermediate or highOD
RS was >90%, and such patients may beneﬁt from adjuvant
chemotherapy.
Our study has several limitations. First, our results may be hard
to generalize. We retrospectively reviewed MR images at a single
tertiary academic institution using a single machine and MR
protocol in limited, homogeneous condition. Second, the number
of intermediate or high OD risk patients was relatively small
compared to the number of low-risk patients. However,
considering OD assay was usually performed in patients expected
to be low risk, this was inevitable. Also, in clinical practice,
patients with intermediate risk usually undergo adjuvant
chemotherapy. Therefore, we divided the study population into
low (RS<18) and non-low (RS ≥18) OD risk groups for
statistical robustness and clinical reality. The number of non-low
OD risk patients (22/67, 32.8%) was not small. Third, large
number of extracted radiomics features and relatively small
sample size may lead to model overﬁtting limiting the
generalizability of the results. Additional validation study is
needed. Fourth, we did not perform intra- or inter-observer
reproducibility of radiomics feature extraction or Rad-score.
However, Huang et al[26] analyzed inter-observer and intra-
observer reproducibility of radiomics feature extraction using
inter- and intra-class correlation coefﬁcients (ICCs), and reported
good agreement (ICC>0.75). Fifth, the clinical signiﬁcance of
our results might be underestimated as our methodology for
manual ROI drawing was time-consuming and labor-intensive.
There are automatic and semi-automatic ROI segmentation
algorithms that do not suffer from disadvantages of manual
approach, which is left for future work. Our research shows
possibilities for using a radiomics signature for risk stratiﬁcation
as a proof of concept study. In addition, our volumetric
measurement could reﬂect the true tumor heterogeneity instead
of single slice. Finally, we constructed the Rad-scores using linear
combination of the selected features and non-linear method of
could offer better performance. Such non-linear models require
more samples than we currently have and thus is left for future
work.
In conclusion, this study revealed that the Rad-score
incorporating radiomics features of DCE-MRI is a signiﬁcant
predictor for discriminating between low and non-low OD risk
groups in patients with ER-positive invasive breast cancers. The
radiomics signature (Rad-score) showed the potential for non-
invasive prediction of which ER-positive patients might have
little-to-no beneﬁt from adjuvant chemotherapy.Author contributions
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